Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment. METHODS: Data were collected from a multiphase, doubleblind, placebo-controlled study that assessed the efficacy of venlafaxine extended release (ER) during 2 sequential 1-year maintenance phases (A and B) in patients with recurrent major depressive disorder (MDD). The primary outcome was the cumulative probability of tachyphylaxis in patients receiving venlafaxine ER, fluoxetine, or placebo. Tachyphylaxis was defined as Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) score

publication date

  • January 1, 2009

Research

keywords

  • Cyclohexanols
  • Depressive Disorder, Major
  • Selective Serotonin Reuptake Inhibitors
  • Tachyphylaxis

Identity

PubMed Central ID

  • PMC3806307

Scopus Document Identifier

  • 77952963486

PubMed ID

  • 19752838

Additional Document Info

volume

  • 42

issue

  • 3